Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) had its price objective hoisted by equities researchers at Robert W. Baird from $8.00 to $10.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's target price points to a potential upside of 1.42% from the company's current price.
A number of other research firms have also issued reports on MRVI. Royal Bank of Canada upped their price target on Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Craig Hallum assumed coverage on Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a "buy" rating and a $15.00 price target for the company. Finally, Stifel Nicolaus lowered their price objective on Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.44.
Get Our Latest Research Report on MRVI
Maravai LifeSciences Price Performance
Shares of Maravai LifeSciences stock traded up $0.99 during mid-day trading on Thursday, reaching $9.86. 5,156,885 shares of the stock traded hands, compared to its average volume of 2,509,447. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average of $8.09 and a 200 day moving average of $6.73. The stock has a market capitalization of $2.48 billion, a PE ratio of -10.47 and a beta of 0.03. Maravai LifeSciences has a fifty-two week low of $4.52 and a fifty-two week high of $16.62.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). The company had revenue of $74.14 million during the quarter, compared to analysts' expectations of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. On average, analysts predict that Maravai LifeSciences will post -0.15 EPS for the current year.
Institutional Investors Weigh In On Maravai LifeSciences
Several institutional investors and hedge funds have recently modified their holdings of MRVI. Gladius Capital Management LP purchased a new stake in Maravai LifeSciences during the fourth quarter worth about $30,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Maravai LifeSciences by 96.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company's stock valued at $34,000 after purchasing an additional 1,662 shares in the last quarter. Signaturefd LLC increased its stake in Maravai LifeSciences by 99.9% during the 3rd quarter. Signaturefd LLC now owns 3,364 shares of the company's stock worth $34,000 after buying an additional 1,681 shares during the period. Performa Ltd US LLC lifted its holdings in Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company's stock worth $39,000 after buying an additional 3,175 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Maravai LifeSciences in the 1st quarter valued at approximately $42,000. Hedge funds and other institutional investors own 50.25% of the company's stock.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
